These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36593061)

  • 1. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
    Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
    In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
    Chon YE; Kim DY; Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
    Clin Mol Hepatol; 2024 Jul; 30(3):345-359. PubMed ID: 38468561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.
    Shao YY; Feng YH; Yen CJ; Yang TS; Shen YC; Chao Y; Chen JS; Su CY; Chen WJ; Hsiang HL; Hsu CH
    J Formos Med Assoc; 2022 Dec; 121(12):2430-2437. PubMed ID: 36153210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year.
    Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
    Cancer Res Treat; 2024 Oct; 56(4):1231-1239. PubMed ID: 38810969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lu J; Lin X; Teng H; Zheng Y
    J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
    Miura R; Ono A; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Kawaoka T; Miki D; Tsuge M; Hayes CN; Oka S
    Medicine (Baltimore); 2024 Aug; 103(34):e39289. PubMed ID: 39288227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
    Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik YH
    Gut Liver; 2024 Jul; 18(4):709-718. PubMed ID: 38932499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.
    Cheon J; Yoo C; Hong JY; Kim HS; Lee DW; Lee MA; Kim JW; Kim I; Oh SB; Hwang JE; Chon HJ; Lim HY
    Liver Int; 2022 Mar; 42(3):674-681. PubMed ID: 34792284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.
    Akyildiz A; Guven DC; Ozluk AA; Ismayilov R; Mutlu E; Unal OU; Yildiz I; Iriagac Y; Turhal S; Akbas S; Bayram E; Telli TA; Turkoz FP; Ozcelik M; Erciyestepe M; Selvi O; Gulbagci B; Erturk I; Isleyen ZS; Kahraman S; Akdag MO; Hamitoglu B; Unek IT; Unal C; Hacibekiroglu İ; Arslan C; Azizy A; Helvaci K; Demirci U; Dizdar O; Basaran M; Goker E; Sendur MA; Yalcin S
    Medicine (Baltimore); 2023 Nov; 102(45):e35950. PubMed ID: 37960746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
    Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.